M. Hayashi et al. / Tetrahedron Letters 43 (2002) 1461–1464
1463
MeO
MeO
MeO
OMe
OMe
OMe
MeHN O
HO
O
O
O
O
i
ii
iii
12
HO
HO
O
Me
15
Me
14
13
OMe
R
MeO
OMe
OMe
OMe
MeN
OMe
iv
vi
vii
HO
NMe
CO2Me
CHO
HO
O
Me
NMe
O
CO2Me
16 : R = H
17 : R = CO2Me
v
18
(R)-(–)-4
Scheme 4. Reagents and conditions: (i) Dess–Martin periodinane, CH2Cl2 (88%). (ii) MeLi, CeCl3, THF or MeLi, THF, −78°C.
(iii) MeNH3Cl, Me3Al, THF, reflux (62%, two steps). (iv) LiAlH4, dioxane, reflux. (v) ClCO2Me, Hu¨nig base, CH2Cl2 (73%, two
steps). (vi) NaIO4, THF–H2O (1:1). (vii) 10% KOH–MeOH (1:5) (49%, two steps).
methanol containing potassium hydroxide,12 the keto-
aldehyde 18 furnished, via a consecutive intramolecular
aldol reaction and dehydration, the cyclohexenone (R)-
(−)-4, [h]2D7 −34.2 (c 0.4, CHCl3) {Ref. 6: [h]2D7 −34.4 (c
0.4, CHCl3)}, which was used as the key intermediate in
the synthesis of the Sceletium alkaloids. The overall
yield of the key intermediate (R)-(−)-4 from the
hydroxy-lactone 12 was 20% in seven steps. Thus, a
new route to the key 4,4-disubstituted cyclohexenone
intermediate (R)-(−)-4 has been developed using the
readily accessible cyclopentane chiral building block
(+)-2. From the intermediate (R)-(−)-4, the Sceletium
alkaloids were obtained: (−)-mesembrine in one step,6
(−)-tortuosamine in five steps,6 and (+)-sceletium A4 in
six steps.6 Although it took 15 steps to convert the
starting chiral cyclopentane (+)-2 into the key cyclo-
hexenone (R)-(−)-4, the present synthesis may be more
easily carried out than the two previous ones since no
intractable reagents or difficult conditions are involved.
The present procedure may also be applicable to the
synthesis of the morphine alkaloids since we also have
developed13 the enantio- and diastereo-selective route to
morphinanone derivatives via the 4,4-disubstituted
cyclohexenone intermediate closely related to 4 (Scheme
4).
Acknowledgements
We are grateful to the Ministry of Education, Culture,
Sports, Science and Technology, Japan for support of
this research.
References
1. Nakashima, H.; Sato, M.; Taniguchi, T.; Ogasawara, K.
Synthesis 2000, 817.
2. (a) Nakashima, H.; Sato, M.; Taniguchi, T.; Ogasawara,
K. Synlett 1999, 1754; (b) Nakashima, H.; Sato, M.;
Taniguchi, T.; Ogasawara, K. Tetrahedron Lett. 2000, 41,
2639; (c) Tanaka, K.; Nakashima, H.; Taniguchi, T.;
Ogasawara, K. Org. Lett. 2000, 2, 1754; (d) Sato, M.;
Nakashima, H.; Hanada, K.; Hayashi, M.; Honzumi, M.;
Taniguchi, T.; Ogasawara, K. Tetrahedron Lett. 2001, 42,
1049; (e) Tanaka, K.; Taniguchi, T.; Ogasawara, K.
Tetrahedron Lett. 2001, 42, 2833.
3. (a) Ogasawara, K. J. Syn. Org. Chem. Jpn. 1999, 57, 957;
(b) For a recent effort, see: Fujimura, T.; Nakashima, H.;
Sakagami, H.; Taniguchi, T.; Ogasawara, K. Tetrahedron
Lett. 2002, 43, 97.
In conclusion, we have demonstrated a transformation
of the chiral cyclopentane chiral building block into a
chiral 4,4-disubstituted cyclohexenone used as the key
4. For reviews of the chemistry of the Sceletium alkaloids,
see: (a) Jeffs, P. W. In The Alkaloids; Manske, R. H. F.;
Rodrigo, R. G. A., Eds.; Academic Press, 1981; Vol. 19,
p. 1; (b) Martin, S. F. In The Alkaloids; Brossi, A., Ed.;
Academic Press, 1987; Vol. 30, p. 251; (c) Hoshino, O. In
The Alkaloids; Cordell, G. A., Ed.; Academic Press, 1998;
Vol. 51; p. 323; (d) Lewis, J. N. Nat. Prod. Rep. 2001, 18,
95 and the preceding reviews.
intermediate of the Sceletium alkaloids using
a
cyclopentanone–cyclohexenone transformation path-
way. We have, thus, extended the utility of the
cyclopentane that we obtained as a chiral building
block.